25 years of p53 book

2005, XI, 446 p., Hardcover
ISBN: 1-4020-2920-9

Table of contents
Ordering information

Edited by
Pierre Hainaut
International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France

Klas G. Wiman
Karolinska Institute, Dept. of Oncology-Pathology, Cancer Center Karolinska (CCK), Stockholm, Sweden

The discovery of p53 in 1979 marks the beginning of a most fascinating era of modern cancer research and molecular biology, an era that is still in full swing and does not show any signs of ending in the foreseeable future. p53 has emerged as a key tumor suppressor and important target for novel cancer therapy. For around 10 years, p53 was considered an oncogene with somewhat unusual features. However, a major paradigm shift occurred around 1988-89 when exciting new findings demonstrated that normal (wild type) p53 could inhibit transformation of cells in culture and that the p53 gene was mutated in a large fraction of human tumors. In fact, p53 appeared to be the most frequently mutated gene in cancer cells. Subsequent work during the 1990’s showed that p53 was a transcription factor that regulates many other genes, and that p53 can trigger apoptosis, the suicide program of the cell.

This book, written by world-leading p53 researchers including many of those who have shaped the field over the past 25 years, provides unique insights into the progress of the p53 field and the prospects for better cancer diagnosis and therapy the future. It should be of interest to everybody working in cancer research, clinical oncology, and molecular biology, and indeed to anybody interested in science, medicine, as well as in recent developments of the ideas and concepts of the molecular biology of cancer.

Table of contents

Chapter 1: The First Twenty-Five Years of p53 Research; Harlan Robins, Gabriela Alexe, Sandra Harris and A.J. Levine

Chapter 2: Regulation of p53 DNA Binding; Kristine McKinney and Carol Prives

Chapter 3: 20 Years of DNA Damage Signaling to p53; Kevin G. McLure and Michael B. Kastan

Chapter 4: Gatekeepers of the Guardian: p53 Regulation by Post-Translational Modification, MDM2 and MDMX; Geoffrey M. Wahl, Jayne M. Stommel, Kurt Krummel and Mark Wade

Chapter 5: Regulation of the p53 Response by Cellular Growth and Survival Factors; Lauren Brown and Samuel Benchimol

Chapter 6: p53, Cell Cycle Arrest and Apoptosis; Shulin Wang and Wafik S. El-Deiry

Chapter 7: p53 Has a Direct Pro-apoptotic Action at the Mitochondria; Ute M. Moll

Chapter 8: Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor; Lawrence A. Donehower, Dora Bocangel, Melissa Dumble and Guillermina Lozano

Chapter 9: p53, p63, and p73: Internecine Relations? Frank McKeon and Annie Yang

Chapter 10: p73, p63 and Mutant p53: Members of Protein Complexs Floating in Cancer Cells; Olimpia Monti, Alexander Damalas, Sabrina Strano and Giovanni Blandino

Chapter 11: p53: Gatekeeper, Caretaker or Both? Carlos P. Rubbi and Jo Milner

Chapter 12: Analysis of p53 Gene Alterations in Cancer: A Critical View; Thierry Soussi

Chapter 13: Patterns of TP53 Mutations in Human Cancer: Interplay Between Mutagenesis, DNA Repair and Selection; Hong Shi, Florence Le Calvez, Magali Olivier and Pierre Hainaut

Chapter 14: Prognostic and Predictive Value of TP53 Mutations in Human Cancer; Magali Olivier, Pierre Hainaut and Anne-Lise Børresen-Dale

Chapter 15: p53 Links Tumor Development to Cancer Therapy; Michael T. Hemann and Scott W. Lowe

Chapter 16: Novel p53-Based Therapies: Strategies and Future Prospects; Sonia Lain and David Lane

Chapter 17: Wild Type p53 Conformation, Structural Consequences of p53 Mutations and Mechanisms of Mutant p53 Rescue; Andreas C. Joerger, Assaf Friedler and Alan R. Fersht

Chapter 18: Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy; Galina Selivanova, Vladimir J.N. Bykov and Klas G. Wiman

Chapter 19: Novel Approaches to p53-Based Therapy: ONYX-015; Frank McCormick

Chapter 20: p53 as Seen by an Outsider; George Klein